{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:29:46Z","timestamp":1788521386406,"version":"build-2803163510"},"reference-count":31,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.2967\/jnumed.123.266654","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T19:40:41Z","timestamp":1709235641000},"page":"541-547","source":"Crossref","is-referenced-by-count":4,"title":["The Impact of Baseline PSMA PET\/CT Versus CT on Outcomes of<sup>223<\/sup>Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients"],"prefix":"10.2967","volume":"65","author":[{"given":"Dianne","family":"Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim J.M.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma M.","family":"Oving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk N.J.","family":"Wyndaele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo E.","family":"Weijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Dick","family":"van Schelven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J.G.","family":"Oyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik T.","family":"te Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addy C.M.","family":"van de Luijtgaarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Nagarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Hermsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"van der Doelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"2024061312401054000_65.4.541.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1701695"},{"key":"2024061312401054000_65.4.541.2","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698"},{"key":"2024061312401054000_65.4.541.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.10.055"},{"key":"2024061312401054000_65.4.541.4","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0210"},{"key":"2024061312401054000_65.4.541.5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22991"},{"key":"2024061312401054000_65.4.541.6","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res."},{"key":"2024061312401054000_65.4.541.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2955"},{"key":"2024061312401054000_65.4.541.8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx044"},{"key":"2024061312401054000_65.4.541.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2024061312401054000_65.4.541.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70183-4"},{"key":"2024061312401054000_65.4.541.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw065"},{"key":"2024061312401054000_65.4.541.12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","article-title":"EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401054000_65.4.541.13","unstructured":"Summary of product characteristics: Xofigo. European Medicines Agency website. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xofigo-epar-product-information_en.pdf. Published November 28, 2013. Updated October 30, 2023. Accessed February 5, 2024."},{"key":"2024061312401054000_65.4.541.14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41391-017-0020-y","article-title":"Current approaches to incorporation of radium-223 in clinical practice","volume":"21","author":"Parker","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2024061312401054000_65.4.541.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2024061312401054000_65.4.541.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219501"},{"key":"2024061312401054000_65.4.541.17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s00259-019-4258-6","article-title":"68Ga-PSMA PET\/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"46","author":"Heinzel","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024061312401054000_65.4.541.18","first-page":"14","article-title":"Diagnostic value of additional 68Ga-PSMA-PET before 223Ra-dichloride therapy in patients with metastatic prostate carcinoma","volume":"56","author":"Br\u00e4uer","year":"2017","journal-title":"Nucl Med (Stuttg)."},{"key":"2024061312401054000_65.4.541.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178533"},{"key":"2024061312401054000_65.4.541.20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41391-022-00569-8","article-title":"Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy","volume":"26","author":"van der Doelen","year":"2023","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2024061312401054000_65.4.541.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2024061312401054000_65.4.541.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2024061312401054000_65.4.541.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233817"},{"key":"2024061312401054000_65.4.541.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05283-6"},{"key":"2024061312401054000_65.4.541.25","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/ijc.32851","article-title":"A prospective observational registry evaluating clinical outcomes of radium-223 treatment in a nonstudy population","volume":"147","author":"Badrising","year":"2020","journal-title":"Int J Cancer."},{"key":"2024061312401054000_65.4.541.26","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0039"},{"key":"2024061312401054000_65.4.541.27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s12149-020-01501-7","article-title":"Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with 223radium-dichloride: a national multicenter study","volume":"34","author":"Frantellizzi","year":"2020","journal-title":"Ann Nucl Med."},{"key":"2024061312401054000_65.4.541.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2514"},{"key":"2024061312401054000_65.4.541.29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3696"},{"key":"2024061312401054000_65.4.541.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265489"},{"key":"2024061312401054000_65.4.541.31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bju.15930","article-title":"Prostate-specific membrane antigen positron emission tomography-computed tomography use prior to systemic therapy in metastatic castration-resistant prostate cancer","volume":"131","author":"Kelly","year":"2023","journal-title":"BJU Int."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:44:39Z","timestamp":1718307879000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.2967\/jnumed.123.266654"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266654","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}